Self-injury is one of the most difficult behaviors associated with autism and other developmental or intellectual disabilities, and a private facility outside Boston that takes on some of the hardest-to-treat cases is embroiled in a major debate: Should it use electrical skin shocks to try to keep patients from harming themselves or others? Continue reading
Americans are a small step closer to accessing less-expensive specialty drugs known as biologics. The Food and Drug Administration for the first time accepted an application for the approval of a copycat “generic” version of the brand name drug Neupogen, which treats patients with low white blood cell counts Continue reading
As of January of this year, there were more than 460 e-cigarette brands available for purchase online, and around 7,700 flavors, including Swedish fish, roasted marshmallow and vanilla cupcake. Continue reading
This May, Colorado’s governor signed the nation’s first “right to try” bill, which allows terminally ill patients to try unapproved — and potentially dangerous — drugs outside of clinical trials and without approval from federal regulators. Continue reading
If you were dying and had exhausted all conventional treatment options, wouldn’t you want immediate access to a drug that might prove to be a miracle cure? That’s the promise of proposed legislation that could make Missouri the third state in the country to enact a so-called “Right to Try” law, which aims to get investigational drugs into the hands of terminally ill patients as quickly as possible. Continue reading
Terminally ill patients often are frustrated to hear about experimental drugs they think might help them, but have not yet been approved by the Food and Drug Administration — a process that often takes years.
Vermont recently became the first state to require labeling of genetically modified organisms (GMOs). Bills and ballot initiatives are pending in many more. What about the rest of the country? And does labeling matter? Continue reading